Thomas Catinazzo Sells 17,717 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 17,717 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $18.69, for a total transaction of $331,130.73. Following the transaction, the chief financial officer owned 159,744 shares in the company, valued at approximately $2,985,615.36. This trade represents a 9.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Monday, June 22nd, Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock. The stock was sold at an average price of $16.97, for a total transaction of $3,176,156.11.
• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $12.86, for a total transaction of $227,840.62.
• On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The stock was sold at an average price of $14.79, for a total transaction of $14,375.88.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $27,000.00.

Relay Therapeutics Stock Up 5.7%

RLAY stock opened at $20.75 on Friday. The firm has a market cap of $3.98 billion, a PE ratio of -13.22 and a beta of 1.67. The business has a 50 day moving average of $15.16 and a 200-day moving average of $11.89. Relay Therapeutics, Inc. has a 12-month low of $3.03 and a 12-month high of $20.79.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.58 million. On average, research analysts expect that Relay Therapeutics, Inc. will post -1.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RLAY. Raymond James Financial reiterated a “strong-buy” rating on shares of Relay Therapeutics in a research note on Tuesday, May 19th. Oppenheimer increased their price target on shares of Relay Therapeutics from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. JPMorgan Chase & Co. assumed coverage on shares of Relay Therapeutics in a report on Wednesday. They set an “overweight” rating and a $28.00 price objective for the company. Citigroup reaffirmed an “outperform” rating on shares of Relay Therapeutics in a research report on Wednesday, May 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $23.73.

Institutional Trading of Relay Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. KBC Group NV purchased a new stake in shares of Relay Therapeutics during the 1st quarter valued at approximately $34,000. Torren Management LLC purchased a new position in Relay Therapeutics in the 4th quarter valued at approximately $30,000. Smartleaf Asset Management LLC raised its holdings in Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Relay Therapeutics during the 4th quarter valued at $46,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Relay Therapeutics by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after acquiring an additional 1,757 shares in the last quarter. Institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.